Pharmaceutical Operations & Technology
|Workplace||Baar, Central Switzerland, Switzerland|
Biogen’s commitment to improving the lives of patients guides every aspect of our manufacturing operations. We take our responsibility of making and delivering quality medicine very seriously. We have been successfully manufacturing large molecule therapies for over two decades. In recent years we have extended our expertise into the production of small molecule therapies and have fully integrated an oral solid dose facility into our manufacturing infrastructure.
We attribute our success to excellence in several key areas. Our process development team continually advances our understanding of the biology and the process technology that are both critical to improving our capabilities and output. Our advanced engineering teams ensure that our manufacturing plants are state of the art with cutting-edge technologies to meet demand for our existing therapies, clinical trials and opportunities in biosimilars. Our world-class manufacturing teams are the key to efficient and reliable operation of these assets. Thorough business continuity planning provides redundancy on a global level to ensure product availability. In addition, these teams create systems that minimize our impact on the environment by limiting waste and using resources efficiently.
Our quality team manages compliance and supervises consistent and dependable production of our therapies, while our supply chain group makes sure that we are able to get our therapies to patients, when and where they need them. The combination of these skills and focuses enable us to manufacture and supply medicines to patients in more than 90 countries.
In the coming years we expect to substantially increase our production capabilities by focusing on innovation that allows us to scale in advance of new pipeline products. Today we can rapidly increase production of small molecules and biologics, providing flexibility and protection to our supply chain.
Biogen operates several manufacturing facilities around the world. Together, they total 198,000 liters of bioreactor capacity, one of the largest among biotech companies worldwide.
Research Triangle Park in North Carolina
In 2013, RTP won the Facility of the Year award in the facility integration category from the International Society for Pharmaceutical Engineering, Pharmaceutical Processing magazine and INTERPHEX, one of the industry’s leading trade events. With this facility we introduced an innovative process for early-stage clinical products. Single-use technology in a closed system replaces the traditional stainless-steel systems. This increases flexibility and speed of supplying drugs for clinical studies, and reduces the environmental impacts of the manufacturing process.
Construction on this next-generation biologics manufacturing facility began in 2016 and is expected to be operational by the end of 2020. The Solothurn facility will produce up to ten metric tons of antibody per year, helping us provide meaningful therapies to patients with serious medical conditions around the globe.
View Solothurn Manufacturing Careers
In your application, please refer to myScience.ch and reference JobID 55774.
More job offers worldwide on jobs.myScience.org
Related Continuing Education Programs
- » Management of Clinical Trials (2021)
- » Recherche clinique orientée patients (2021)
- » Qualité et Sécurité des soins : dimensions opérationnelles (2022)
- » Pharmacie clinique - Pharmacothérapie (2021)
- » Toxicology (2020)
- » Drug Discovery and Clinical Development (2020)
- » Management of Clinical Trials (2020)
- » Toxicology (2020)
- » Pharmacie clinique - Pharmacothérapie (2020)
- » Medicines and Medical Devices in Emergency and Disaster (2020)
29 March 2022
An approach to treating a severe congenital myopathy
» More news